In a completely different context, the increased sensitivity of cells to DNA damage when DYRK1A is depleted could be therapeutically exploited for cancer treatment by combining DYRK1A inhibitors and genotoxic drugs in cancer types in which DYRK1A inhibitors have an impact on the tumoral cell16. The gene discussed is DYRK1A; the disease is cancer.